Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
PR Newswire; Tuesday, June 30, 1998
Although scientists have long suspected an association between HIV and STDs, the connection remains elusive. Senior author Ronald H. Gray, professor, Population Dynamics, the Johns Hopkins School of Public Health, said, "Given the significant impact that our mass treatment campaign in Uganda had on STDs, it's disappointing to find no differences in HIV incidence between the treated and untreated populations."
The study, which enrolled a total of 15,127 HIV-negative subjects, was conducted in Rakai District, a rural region in southwestern Uganda with a high prevalence of HIV infection (15.9 percent). In the intervention arm of the trial, the scientists brought an intensive STD control strategy into participants' homes and provided entire communities with broad-spectrum antibiotic treatment for STDs ("mass treatment").
Control-arm subjects whose blood tests revealed syphilis, or who reported current STD symptoms during the interviews, were referred during the 10-monthly visits for free treatment provided by the project itself.
At follow-up after mass STD treatment, the prevalences of syphilis, trichomonas, bacterial vaginosis, gonorrhea, and chlamydia were lower in the intervention arm compared to the control arm; and these differences were particularly marked and statistically significant among pregnant women. Despite these significant differences in STD rates realized between study arms, STD control had no effect on HIV incidence, and HIV incidence was especially high in pregnant women. In contrast, a trial in Mwamza, Tanzania, found a 38 percent lower HIV incidence among subjects receiving clinic-based treatment for symptomatic STDs.
The scientists think it unlikely that problems in study design or follow-up account for the failure to lower HIV incidence in the Rakai district. Treatment coverage was high. Over 80 percent of all eligible adults in the communities (and over 90 percent of those enrolled) accepted treatment. The researchers felt that the fact that STD services were offered to control subjects would not explain the absence of any effect on HIV, since few symptomatic persons used these services.
Gray said that "our data show that STDs increase the risk of HIV infections at an individual level, but with the high background prevalence of HIV, most HIV transmission occurs independently of STD transmission."
The earlier Mwamza trial involved a population with an HIV infection rate of 4.1 percent, whereas the epidemic in Rakai was "mature," with 15.9 percent of the population HIV-positive. Gray said, "This trial raises important questions with regard to future policies on STD control and HIV prevention and thus it is imperative to determine whether the divergent findings between our trial and the one in Mwamza reflect differences in the stage of the two HIV epidemics." Gray called for a collaborative reassessment by the two research teams, as well as new trials in regions where HIV incidence is high and where it is low. The study was supported by grants from the National Institute of Allergy and Infectious Diseases; the National Institute of Child Health and Development; the U.S. National Institutes of Health; the Rockefeller Foundation; and the World Bank Uganda STI Project and John Snow Inc.
SOURCE: Johns Hopkins School of Public Health
980630
PR980619
Copyright © 1998 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .